Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) hit a new 52-week high during trading on Tuesday . The company traded as high as $3.15 and last traded at $3.02, with a volume of 16504 shares changing hands. The stock had previously closed at $2.78.

EYPT has been the subject of a number of research reports. ValuEngine raised Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 29th. Zacks Investment Research raised Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 28th. Finally, HC Wainwright reissued a “buy” rating and set a $2.50 price target on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, June 26th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Eyepoint Pharmaceuticals has a consensus rating of “Buy” and an average target price of $4.85.

The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 1.48. The stock has a market cap of $140.48 million, a PE ratio of -4.86 and a beta of 0.98.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, September 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 1,795.71% and a negative return on equity of 301.45%. The firm had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $0.67 million. analysts anticipate that Eyepoint Pharmaceuticals Inc will post -0.42 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. FineMark National Bank & Trust purchased a new stake in Eyepoint Pharmaceuticals during the second quarter valued at about $118,000. California Public Employees Retirement System purchased a new stake in Eyepoint Pharmaceuticals during the second quarter valued at about $135,000. Creative Planning purchased a new stake in Eyepoint Pharmaceuticals during the second quarter valued at about $162,000. Essex Investment Management Co. LLC purchased a new stake in Eyepoint Pharmaceuticals during the second quarter valued at about $170,000. Finally, Bard Associates Inc. purchased a new stake in Eyepoint Pharmaceuticals during the second quarter valued at about $189,000. 62.93% of the stock is owned by hedge funds and other institutional investors.

About Eyepoint Pharmaceuticals (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.

Read More: Short Selling

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.